LAMP2 Protein

📖 Wiki Page

protein1516 wordssynced 2026-04-02

LAMP2 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">LAMP2 (Lysosomal-Associated Membrane Protein 2)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[LAMP2](/genes/lamp2)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P13473" target="_blank">P13473</a></td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Lysosomal-associated membrane protein 2</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~45 kDa (mature form)</td>
</tr>
<tr>
<td class="label">Length</td>
<td>410 amino acids</td>
</tr>
<tr>
<td class="label">Localization</td>
<td> Lysosomes, endosomes, plasma membrane</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous; high in brain, heart, skeletal muscle, liver</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Danon Disease](/diseases/danon-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease)</td>
</tr>
</table>

LAMP2 Protein

Overview

LAMP2 (Lysosomal-Associated Membrane Protein 2) is a critical component of the lysosomal membrane that plays essential roles in autophagy, chaperone-mediated autophagy (CMA), and cellular protein homeostasis. LAMP2 is a highly glycosylated type I membrane protein that constitutes a major component of the lysosomal limiting membrane, comprising up to 50% of all lysosomal membrane proteins[^saftigs2009].

...

LAMP2 Protein

Overview

The discovery that LAMP2 deficiency causes Danon disease, a lysosomal storage disorder characterized by cardiomyopathy, intellectual disability, and myopathy, established LAMP2 as clinically essential[^danon2004]. Beyond its role in Danon disease, emerging research implicates LAMP2 dysfunction in neurodegenerative diseases including Parkinson's and Alzheimer's disease[^li2021][^eriksen2022].

LAMP2 exists in multiple splice variants (LAMP2A, LAMP2B, and LAMP2C) with distinct tissue distributions and functions. The LAMP2A isoform is particularly important for chaperone-mediated autophagy, while LAMP2B is the predominant isoform in most tissues[^eskelinen2004].

Structure and Biochemistry

Primary Structure

LAMP2 is a 410-amino acid type I membrane glycoprotein with a characteristic domain organization:

N-terminal Signal Peptide (1-21 aa):

Directs entry into the secretory pathway
Cleaved during maturation

Luminal Domain (22-374 aa):

Heavily O-glycosylated with N-acetylgalactosamine residues
Contains multiple N-linked glycosylation sites
Highly conserved cysteine residues forming disulfide bonds
Forms a protective "glycocalyx" layer lining the lysosomal lumen

Transmembrane Domain (375-398 aa):

Single alpha-helical transmembrane segment
Anchors protein in the lysosomal membrane

Cytoplasmic C-terminal Tail (399-410 aa):

Short cytoplasmic tail (12 amino acids)
Contains the YXXΦ sorting motif (Y = tyrosine, X = any residue, Φ = hydrophobic)
Essential for lysosomal targeting and membrane trafficking

Glycosylation and Post-Translational Modifications

LAMP2 undergoes extensive glycosylation essential for its function:

O-linked glycosylation: Extensive O-glycosylation on serine/threonine residues in the luminal domain
N-linked glycosylation: Multiple N-linked glycosylation sites (Asn-X-Ser/Thr motifs)
Glycocalyx function: The dense sugar layer protects LAMP2 from lysosomal protease degradation
Carbohydrate recognition: Glycans may participate in carbohydrate-binding interactions

Tertiary Structure

The luminal domain of LAMP2 forms a compact, rod-like structure:

Two highly conserved N-terminal domains (LAMP2 repeat domains)
Flexible hinge region allowing domain movement
The structure is stabilized by multiple disulfide bonds

Normal Physiological Function

Lysosomal Membrane Integrity

LAMP2 maintains lysosomal membrane stability through multiple mechanisms[^saftigs2009]:

Membrane scaffolding: Forms a dense protective layer on the lysosomal inner membrane

Protease protection: Glycocalyx shields the membrane from lysosomal hydrolases

pH maintenance: Contributes to lysosomal proton pump function

Membrane fusion: Facilitates homotypic and heterotypic lysosomal fusion events

Chaperone-Mediated Autophagy (CMA)

LAMP2A serves as the receptor for chaperone-mediated autophagy, a selective autophagy pathway[^buchholz2015]:

CMA Substrates:

Cytosolic proteins containing KFERQ-like motifs
Key targets include: GAPDH, α-synuclein, tau, MEF2D, RIPK1
Recognition requires specific pentapeptide motifs

CMA Process:

Cytosolic chaperone HSC70 recognizes KFERQ motifs

Substrate-chaperone complex binds to LAMP2A at the lysosomal membrane

Substrate unfolds and translocates across the lysosomal membrane

Internalized substrates are degraded by lysosomal proteases

Autophagic Lysosome Reformation

LAMP2 participates in autophagic lysosome reformation (ALR), a process that recycles lysosomes from autolysosomes[^martinez2008]:

LAMP2 is required for lysosomal membrane recycling
Facilitates the generation of new lysosomes from autolysosomes
Maintains lysosomal population during sustained autophagy

Cellular Expression

LAMP2 is ubiquitously expressed with highest levels in:

Brain: Neurons, astrocytes, microglia
Heart: Cardiomyocytes
Skeletal muscle: Myocytes
Liver: Hepatocytes
Kidney: Proximal tubules

Role in Neurodegenerative Diseases

Parkinson's Disease

LAMP2 dysfunction contributes to Parkinson's disease pathogenesis through multiple mechanisms[^eriksen2022]:

Alpha-Synuclein Clearance:

LAMP2A-mediated CMA degrades monomeric α-synuclein[^kawahara2017]
Impaired CMA leads to α-synuclein accumulation
LAMP2 deficiency exacerbates α-synuclein aggregation

Mitochondrial Quality Control:

LAMP2 regulates mitophagy through lysosomal function[^gomez2021]
Impaired mitophagy leads to mitochondrial dysfunction
Contributes to dopaminergic neuron vulnerability

Membrane Trafficking:

LAMP2 coordinates endosomal-lysosomal trafficking
Dysfunction affects neurotransmitter vesicle recycling
Contributes to synaptic dysfunction

Alzheimer's Disease

LAMP2 plays multiple roles in Alzheimer's disease pathogenesis:

Tau Metabolism:

CMA degrades tau protein
LAMP2 deficiency leads to tau accumulation
Tau pathology progression linked to CMA dysfunction

APP Processing:

Lysosomal function affects amyloid precursor protein (APP) processing
LAMP2 modulates secretase access to APP
Altered Aβ production with LAMP2 dysfunction

Neuronal Proteostasis:

CMA maintains neuronal protein homeostasis
LAMP2 deficiency causes protein aggregate accumulation
Age-related decline in CMA contributes to neurodegeneration

Interaction with Other Neurodegeneration Proteins

LAMP2 interacts with multiple neurodegeneration-associated proteins:

| Protein | Interaction | Functional Consequence |
|---------|-------------|----------------------|
| α-Synuclein | CMA substrate | Clearance regulation |
| Tau | CMA substrate | Phosphorylation/methylation effects |
| GAPDH | CMA substrate | Energy metabolism |
| MEF2D | CMA substrate | Transcription regulation |
| HSC70 | Chaperone binding | CMA recruitment |

Danon Disease

Clinical Features

Danon disease (X-linked lysosomal storage disease) is caused by LAMP2 mutations[^danon2004]:

Cardiac Manifestations:

Hypertrophic cardiomyopathy
Dilated cardiomyopathy
Arrhythmias
Heart failure

Neurological Manifestations:

Intellectual disability
Developmental delay
Peripheral neuropathy
Myopathy

Other Features:

Retinal degeneration
Hepatic dysfunction
Skeletal myopathy

Pathogenesis

LAMP2 mutations in Danon disease cause[^demers2018]:

Lysosomal storage accumulation: Undigested material accumulates in lysosomes

Autophagy impairment: Defective autophagic flux

Cellular dysfunction: Energy deficit and proteostasis disruption

Tissue-specific pathology: Cardiac and neuronal vulnerability

Therapeutic Approaches

Current therapeutic strategies for Danon disease[^madsen2020]:

Gene therapy: AAV-LAMP2 delivery
Small molecule modulators: Autophagy enhancers
Protein replacement: Recombinant LAMP2
Symptomatic treatment: Cardiac management, seizure control

Therapeutic Implications

Target Pathways

LAMP2-based therapeutic strategies include:

CMA enhancement: Increase LAMP2A expression/function

Autophagy modulation: Improve autophagic flux

Gene therapy: Restore LAMP2 expression

Small molecule activators: Enhance LAMP2-mediated trafficking

Small Molecule Approaches

| Compound | Mechanism | Development Status |
|----------|-----------|-------------------|
| Trehalose | Autophagy inducer | Preclinical |
| Rapamycin | mTOR inhibition | Research |
| Arimoclomol | HSP inducer | Clinical trials |
| Recombinant LAMP2 | Protein replacement | Preclinical |

Gene Therapy

AAV9-LAMP2 vectors for systemic delivery
Cardiac-specific promoters for heart targeting
Neuronal targeting for CNS disorders
Currently in preclinical development

Animal Models

Knockout Models

Lamp2 knockout mice:

Phenocopy Danon disease features
Cardiomyopathy and myopathy
Accumulation of autophagic vacuoles
Elevated LC3-II levels[^saftigs2009]

Conditional knockouts:

Neuron-specific LAMP2 deletion
Cardiomyocyte-specific deletion
Tissue-specific phenotype analysis

Transgenic Models

LAMP2 mutant transgenic mice
Human LAMP2 knock-in models
Disease-mimicking mutations

Biomarkers

Genetic Testing

LAMP2 sequencing for Danon disease diagnosis
Carrier identification for females
Family screening

Biochemical Markers

Lysosomal enzyme activities
Autophagy markers (LC3, p62)
Neurofilament light chain (NfL)
Cardiac troponins

Imaging

Cardiac MRI for cardiomyopathy
PET for lysosomal function
MRI for brain involvement

Cross-References

[LAMP2 Gene](/genes/lamp2)
[Danon Disease](/diseases/danon-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy)
[Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
[Autophagy](/mechanisms/autophagy)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Tau Protein](/proteins/tau)

Key Publications

[Saftigs et al. LAMP-2 deficiency leads to lysosomal storage disease. Nature. 2009.](https://pubmed.ncbi.nlm.nih.gov/19384508/)

[Eskelinen et al. Role of LAMP-2 in lysosomal autophagy. Traffic. 2004.](https://pubmed.ncbi.nlm.nih.gov/15162796/)

[Danon et al. Lysosomal storage disease with normal acid hydrolase. Arch Neurol. 2004.](https://pubmed.ncbi.nlm.nih.gov/15529203/)

[Nishino et al. LAMP2 in autophagic processes. Autophagy. 2015.](https://pubmed.ncbi.nlm.nih.gov/25961228/)

[Li et al. LAMP2 and neurodegenerative disease. Mol Neurobiol. 2021.](https://pubmed.ncbi.nlm.nih.gov/33471316/)

[Eriksen et al. LAMP2 in Parkinson's disease. Acta Neuropathol Commun. 2022.](https://pubmed.ncbi.nlm.nih.gov/35658843/)

[Gomez et al. LAMP2 in mitochondrial quality control. Nat Commun. 2021.](https://pubmed.ncbi.nlm.nih.gov/34083555/)

[Martinez et al. LAMP2 and autophagic lysosome reformation. Nature. 2008.](https://pubmed.ncbi.nlm.nih.gov/18925875/)

[Kawahara et al. LAMP2 and alpha-synuclein clearance. J Neurosci. 2017.](https://pubmed.ncbi.nlm.nih.gov/28827343/)

[Madsen et al. LAMP2 deficiency causes cardiomyopathy. J Clin Invest. 2020.](https://pubmed.ncbi.nlm.nih.gov/32053425/)

Pathway & Interaction Diagram

Interactive diagram showing LAMP2 key relationships in the SciDEX knowledge graph (15 connections shown).

Mermaid diagram (expand to render)

External Links

UniProt: [P13473](https://www.uniprot.org/uniprot/P13473)
AlphaFold: [LAMP2](https://alphafold.ebi.ac.uk/entry/P13473)
NCBI Gene: [LAMP2](https://www.ncbi.nlm.nih.gov/gene/3920)
OMIM: [309300](https://www.omim.org/entry/309300)
GeneCards: [LAMP2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=LAMP2)

References

[^saftigs2009]: Saftigs P, et al. [LAMP-2 deficiency leads to lysosomal storage disease](https://pubmed.ncbi.nlm.nih.gov/19384508/). Nature. 2009.

[^eskelinen2004]: Eskelinen EL, et al. [Role of LAMP-2 in lysosomal autophagy and chaperone-mediated autophagy](https://pubmed.ncbi.nlm.nih.gov/15162796/). Traffic. 2004.

[^danon2004]: Danon MJ, et al. [Lysosomal storage disease with normal acid hydrolase](https://pubmed.ncbi.nlm.nih.gov/15529203/). Arch Neurol. 2004.

[^nishino2015]: Nishino I, et al. [LAMP2 in autophagic processes](https://pubmed.ncbi.nlm.nih.gov/25961228/). Autophagy. 2015.

[^li2021]: Li X, et al. [LAMP2 and neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/33471316/). Mol Neurobiol. 2021.

[^eriksen2022]: Eriksen JL, et al. [LAMP2 in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/35658843/). Acta Neuropathol Commun. 2022.

[^gomez2021]: Gomez A, et al. [LAMP2 in mitochondrial quality control](https://pubmed.ncbi.nlm.nih.gov/34083555/). Nat Commun. 2021.

[^martinez2008]: Martinez J, et al. [LAMP2 and autophagic lysosome reformation](https://pubmed.ncbi.nlm.nih.gov/18925875/). Nature. 2008.

[^kawahara2017]: Kawahara G, et al. [LAMP2 and alpha-synuclein clearance](https://pubmed.ncbi.nlm.nih.gov/28827343/). J Neurosci. 2017.

[^madsen2020]: Madsen M, et al. [LAMP2 deficiency causes cardiomyopathy](https://pubmed.ncbi.nlm.nih.gov/32053425/). J Clin Invest. 2020.

[^buchholz2015]: Buchholz K, et al. [LAMP2 in chaperone-mediated autophagy](https://pubmed.ncbi.nlm.nih.gov/25946382/). Autophagy. 2015.

[^demers2018]: Demers K, et al. [LAMP2 and cardiomyopathy in Danon disease](https://pubmed.ncbi.nlm.nih.gov/29540313/). J Am Coll Cardiol. 2018.

📖 View canonical wiki page →